Table 1

Characteristics of 40 perinatal HIV-infected children receiving HAART before 6 months of age.

CDC category

Age at first HAART (years)

First HAART Regimen

Age at first regimen discontinuation (years)

Reason for discontinuation

Age at last follow-up (years)

CD4+ T cells at last follow up (%)

Viral load at last follow-up

(Log10 copies/mL)


B1

0.21

DDI+D4T+LPV/r

6.40

Simplification

9.83

42

<1.69

A1

0.18

3TC+D4T+ LPV/r

6.65

Simplification

8.87

28

1.85

B1

0.26

AZT+3TC+NFV

Ongoing

8.67

38

<1.69

B2

0.48

AZT+3TC+NFV

Ongoing

8.66

37

3.00

A1

0.27

3TC+D4T+NFV

5.00

Simplification

8.75

45

<1.69

A2

0.08

3TC+D4T+NFV

Ongoing

8.81

35

<1.69

B1

0.30

AZT+3TC+NFV

4.47

Simplification

8.03

35

<1.69

A1

0.33

ABC+3TC+NFV

7.17

Virologic failure

7.70

28

2.63

A2

0.44

AZT+3TC+NFV

Ongoing

8.32

33

<1.69

N1

0.34

AZT+3TC+NVP

3.89

Therapy interruption

5.43

38

3.73

A2

0.34

3TC+D4T+NFV

Ongoing

6.94

37

<1.69

A1

0.33

AZT+3TC+NFV

1.50

Therapy interruption

7.41

31

5.10

A1

0.39

DDI+D4T+NFV

5.71

Simplification

7.28

32

4.00

N1

0.21

DDI+D4T+NFV

Ongoing

7.11

30

<1.69

A1

0.34

AZT+3TC+NFV

4.58

Simplification

7.78

44

<1.69

N2

0.13

3TC+D4T+NVP

Ongoing

6.40

44

<1.69

A2

0.28

AZT+3TC+NFV

Ongoing

6.08

25

<1.69

A1

0.30

3TC+D4T+NFV

6.21

Simplification

6.28

43

<1.69

A2

0.18

DDI+D4T+NFV

3.50

Virologic failure

6.03

39

<1.69

B1

0.36

3TC+D4T+NFV

Ongoing

6.24

38

<1.69

A2

0.19

DDI+D4T+NFV

1.64

Therapy interruption

6.56

20

<1.69

N1

0.25

AZT+3TC+NVP

Ongoing

5.19

42

<1.69

N1

0.42

3TC+D4T+NFV

1.71

Virologic failure

4.39

39

<1.69

A1

0.32

3TC+D4T+NFV

4.30

Simplification

5.04

37

<1.69

N1

0.27

AZT+3TC+NFV

3.21

Simplification

5.15

43

<1.69

N1

0.22

3TC+D4T+NFV

Ongoing

4.66

32

<1.69

A1

0.48

AZT+3TC+NVP

Ongoing

5.56

34

<1.69

A1

0.45

AZT+3TC+NFV

2.34

Virologic failure

5.88

39

<1.69

B2

0.15

ABC+D4T+NVP

Ongoing

4.18

32

<1.69

B1

0.45

3TC+D4T+NFV

2.78

Virologic failure

5.06

28

2.34

B2

0.22

3TC+D4T+ LPV/r

3.77

Virologic failure

5.10

38

<1.69

A2

0.14

AZT+3TC+NVP

Ongoing

2.02

51

<1.69

B1

0.43

AZT+3TC+NVP

Ongoing

3.89

36

<1.69

N1

0.31

3TC+D4T+NFV

Ongoing

2.27

35

2.50

B1

0.24

3TC+D4T+NFV

1.69

Virologic failure

3.83

32

<1.69

N1

0.31

AZT+3TC+NFV

Ongoing

0.59

33

2.96

N2

0.25

AZT+3TC+NFV

2.92

Virologic failure

3.41

33

<1.69

N1

0.17

AZT+3TC+NFV

Ongoing

2.18

35

<1.69

B1

0.36

ABC+3TC+LPV/r

0.45

Liver toxicity

2.10

42

<1.69

A1

0.23

3TC+D4T+NFV

Ongoing

0.88

35

<1.69


Note: ZDV, zidovudine; 3TC, lamivudine; D4T, stavudine; DDI, didanosine; NELF, nelfinavir; LPV/r, lopinavir/ritonavir; NEV, nevirapine; ABC: abacavir.

Chiappini et al. BMC Infectious Diseases 2009 9:140   doi:10.1186/1471-2334-9-140

Open Data